Download Octoplus Frp

I want to do a triggered acquisition from our new e2v octoplus (camera link model). I have it connected to a PCIe1433 board. It needs to be synchronized to a TTL trigger (from a DAC controlling galvo mirrors). That triggering model works for another camera.

With the octoplus I can set the camera to external triggered acquisition mode (using the serial commands), but it doesn't acquire any lines in this mode. When I try this with the CameraFileGenerator I get a message with a timeout. When I try it with NI MAX, I get an error message stating no serial termination character is received.

Download Zip 🔥 https://shoxet.com/2y2Pvu 🔥

LEIDEN, THE NETHERLANDS--(Marketwire - April 20, 2009) - OctoPlus N.V. ("OctoPlus" or "theCompany") (EURONEXT: OCTO) announces today that its licensee BiolexTherapeutics (see separate Biolex press release on www.biolex.com) hascommenced patient dosing in the SELECT-2 Phase IIb clinical study ofLocteron, a controlled release formulation of interferon alpha for thetreatment of chronic hepatitis C. Locteron combines OctoPlus' controlledrelease drug delivery technology PolyActive with Biolex' interferonalpha and is the most advanced product in clinical developmentincorporating one of OctoPlus' proprietary drug delivery technologies.In October 2008 OctoPlus entered into an exclusive license and productacquisition agreement with Biolex, worth up to EUR 100 million. As aresult, Biolex holds the full commercial rights to Locteron and isresponsible for development and commercialisation, and OctoPlus is paid byBiolex to perform process development and to manufacture Locteron.The Phase IIb study is being conducted in the United States and Europe in100 treatment-nave, genotype-1, chronic hepatitis C patients. Patientswill be randomised into one of four dosing cohorts, the 320, 480 or 640g dose of Locteron (administered once every two weeks) or a control armconsisting of PEG-Intron (administered every week), with all patientsreceiving weight-based ribavirin. Patients will be treated for 48 weeks andwill be followed for an additional 24 weeks to determine the sustainedvirologic response (SVR) rate. The interim results after 12 weeks oftreatment are expected to be used as the basis for the selection of theLocteron dose(s) for Phase III studies.Simon Sturge, CEO of OctoPlus comments: "Having announced earlier thismonth the seventh company to sign an evaluation contract for OctoPlus'technology, we are now delighted to report this progress in Locteron'sclinical development. The start of Biolex's Phase IIb study of Locteron isa major milestone in the commercialisation of our proprietary PolyActivetechnology. We look forward to the results of this large-scale study inhepatitis C patients, which we hope will demonstrate Locteron's potentialimproved tolerability profile as a result of its controlled releasemechanism."Locteron is an investigational therapeutic candidate and has not beenapproved for sale by the United States Food and Drug Administration or byany international regulatory agency.About LocteronLocteron is a controlled release interferon alpha designed to improvepatient care in the treatment of hepatitis C through a more favorableside-effect profile and dosing convenience compared to existing pegylatedinterferon products. In contrast to Locteron's controlled releasemechanism, the currently approved products Pegasys and PEG-Intron, andthe investigational product Albuferon are immediate release productsthat lack a controlled release mechanism. Interferon alpha serves as thefoundation of current combination therapy for hepatitis C patients, and allmajor hepatitis C drug candidates currently in clinical trials are beingstudied in combination with interferon alpha. It is estimated thatworldwide sales of interferon products for the treatment of hepatitis Cwill approach US$ 6 billion by 2016.Locteron combines OctoPlus' proprietary drug delivery technology PolyActivewith BLX-883, a recombinant interferon alpha produced by Biolex in itspatented LEX System(SM). Locteron is configured to allow dosing once everytwo weeks, more convenient than Pegasys and PEG-Intron, each of whichrequire dosing every week. More importantly, Locteron's controlled releasemechanism results in the gradual release of interferon alpha 2b to patientsover the duration of two weeks and avoids the early peak blood plasmalevels of the active interferon that characterise pegylated interferons andAlbuferon. This controlled release mechanism is designed to reduce thefrequency, duration and severity of side effects, including flu-likesymptoms, commonly experienced by patients treated with pegylatedinterferons and with Albuferon. Three clinical trials with Locteron havebeen completed, and the results of the SELECT-1 Phase IIa trial werepresented at the 43rd Annual Meeting of the European Association for theStudy of the Liver in April 2008.About Biolex TherapeuticsBiolex is a clinical-stage biopharmaceutical company that uses its patentedLEX System(SM) to develop hard-to-make therapeutic proteins and to optimizemonoclonal antibodies. The LEX System is a novel technology thatgenetically transforms the aquatic plant Lemna to enable the production ofbiologic product candidates.About OctoPlusOctoPlus is a product-oriented biopharmaceutical company committed to thecreation of improved pharmaceutical products that are based on OctoPlus'proprietary drug delivery technologies and have fewer side effects,improved patient convenience and a better efficacy/safety balance thanexisting therapies. Rather than seeking to discover novel drug candidatesthrough early stage research activities, OctoPlus focuses on thedevelopment of long-acting, controlled release versions of known proteintherapeutics, other drugs, and vaccines on behalf of its clients.The clinically most advanced product incorporating our technology is BiolexTherapeutics' lead product Locteron, a controlled release formulation ofinterferon alpha for the treatment of chronic hepatitis C. Locteron isbeing manufactured for Biolex by OctoPlus and is currently in Phase IIbclinical studies.In addition, OctoPlus is a leading European provider of advanced drugformulation and clinical scale manufacturing services to the pharmaceuticaland biotechnology industries, with a focus on difficult-to-formulate activepharmaceutical ingredients.OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbolOCTO. For more information about OctoPlus, please visit our websitewww.octoplus.nl.This document may contain certain forward-looking statements relating tothe business, financial performance and results of OctoPlus and theindustry in which it operates. These statements are based on OctoPlus'current plans, estimates and projections, as well as its expectations ofexternal conditions and events. In particular the words "expect,""anticipate," "predict," "estimate," "project," "plan," "may," "should,""would," "will," "intend," "believe" and similar expressions are intendedto identify forward-looking statements. We caution investors that a numberof important factors, and the inherent risks and uncertainties that suchstatements involve, could cause actual results or outcomes to differmaterially from those expressed in any forward-looking statements. In theevent of any inconsistency between an English version and a Dutch versionof this document, the English version will prevail over the Dutch version.

For further information, please contact:

Rianne Roukema

Corporate Communications

telephone number +31 (71) 524 1071

e-mail IR@octoplus.nl

Email thisFacebookTwitterLinkedInPinterestRedditBack to news

Company profile OctoPlus

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies.

OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext Amsterdam under the symbol OCTO. More information about OctoPlus can be found on: www.octoplus.nl ff782bc1db